What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

From a historical perspective, Nike (NKE) is a cheap stock to consider. The retailer, best known for its athletic shoes, lost ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Liraglutide is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) ...

Global Type 1 diabetes market is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...